Test Code LAB692 Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum
Necessary Information
In order to provide the best results, either answer the order entry questions or provide the required information using the Second Trimester Maternal Screening Alpha-Fetoprotein / Quad Screen Patient Information (T595).
Specimen Required
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Do not collect specimen after amniocentesis as this could affect results.
2. Within 2 hours of collection, centrifuge and aliquot serum into a plastic vial.
Additional Information:
1. Collect blood between 15 weeks, 0 days and 22 weeks, 6 days.
2. Initial or repeat testing is determined in the laboratory at the time of report and will be reported accordingly. To be considered a repeat test for the patient, the testing must be within the same pregnancy and trimester, with interpretable results for the same test, and both tests are performed at Mayo Clinic.
Forms
1. If not ordering electronically, Second Trimester Maternal Screening Alpha-Fetoprotein / Quad Screen Patient Information (T595) is required.
2. If not ordering electronically, complete, print, and send a General Request (T239).
Secondary ID
113382Useful For
Prenatal screening for open neural tube defect
Special Instructions
Method Name
Two-Site Immunoenzymatic (Sandwich) Assay
Reporting Name
AFP Single Marker SCRN, Maternal, SSpecimen Type
SerumSpecimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Serum | Refrigerated (preferred) | 14 days |
Frozen | 90 days | |
Ambient | 7 days |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | OK |
Gross icterus | OK |
Reference Values
An alpha-fetoprotein (AFP) multiple of the median (MoM) <2.5 is reported as screen negative.
AFP MoM ≥2.5 (singleton and twin pregnancies) are reported as screen positive.
An interpretive report will be provided.
Cautions
Race, weight, smoking, multiple fetus pregnancy, and insulin-dependent diabetes (IDD) may affect marker concentrations. Black mothers tend to have higher alpha-fetoprotein (AFP) levels but lower risk of neural tube defects and are assigned to a separate AFP median set. Multiple of the medians (MoM) are adjusted for maternal weight (to account for dilution effects in heavier mothers). The AFP is adjusted upward in IDD to account for lower values in diabetic pregnancies. Smoking results in higher second trimester maternal serum AFP. MoM are adjusted accordingly to account for serum AFP differences in smokers.
The screen results are dependent on accurate information for gestation, race, IDD, and weight. Inaccurate information can lead to significant alterations in the estimated risk. In particular, erroneous assessment of gestational age can result in false-positive or false-negative screen results. Because of its increased accuracy, the determination of gestational age by ultrasound is recommended, when possible, rather than by last menstrual period.
A screen-negative result does not guarantee the absence of fetal defects. A screen-positive result does not provide a diagnosis but indicates that further diagnostic testing should be considered (an unaffected fetus may have screen-positive result for unknown reasons).
Valid measurements of AFP in maternal serum cannot be made after amniocentesis.
Triplet and higher multiple pregnancies cannot be interpreted.
Each center offering maternal serum screening to patients should establish a standard screening protocol, which provides pre- and post-screening education and appropriate follow-up for screen-positive results.
In rare cases, some individuals can develop antibodies to mouse or other animal antibodies (often referred to as human anti-mouse antibodies [HAMA] or heterophile antibodies), which may cause interference in some immunoassays. Caution should be used in interpretation of results, and the laboratory should be alerted if the result does not correlate with the clinical presentation.
Day(s) Performed
Monday through Friday
Report Available
4 to 6 daysPerforming Laboratory

Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
82105
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
MAFP1 | AFP Single Marker SCRN, Maternal, S | 48802-3 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
7058 | Recalculated Maternal Serum Screen | 32399-8 |
113146 | Results Summary | 32399-8 |
113147 | Neural tube defect risk estimate | 48803-1 |
10351 | AFP | 83073-7 |
113148 | AFP MoM | 23811-3 |
10356 | INTERPRETATION | 49092-0 |
10357 | RECOMMENDED FOLLOW UP | 80615-8 |
10248 | Additional comments | 48767-8 |
3009 | Specimen collection date | 33882-2 |
7823 | Maternal date of birth | 21112-8 |
7834 | Calculated age at EDD | 43993-5 |
26717 | Maternal Weight | 29463-7 |
26718 | Maternal Weight | 29463-7 |
IDD | Insulin dependent diabetes | 44877-9 |
RACE1 | Patient race | 21484-1 |
SMKNG | Current cigarette smoking status | 64234-8 |
10054 | EDD by U/S scan | 11781-2 |
7203 | GA on collection by U/S scan | 11888-5 |
7753 | EDD by LMP | 11779-6 |
7204 | GA on collection by dates | 11885-1 |
7830 | GA used in risk estimate | 21299-3 |
MULTF | Number of Fetuses | 55281-0 |
CHOR_ | Number of Chorions | 92568-5 |
IVFP | IVF pregnancy | 47224-1 |
PRNTD | Prev Pregnancy w/ Neural Tube Defect | 53827-2 |
PTNTD | Patient or father of baby has a NTD | 53827-2 |
INTL | Initial or repeat testing | 77202-0 |
DRPHN | Physician Phone Number | 68340-9 |
10358 | GENERAL TEST INFORMATION | 62364-5 |